Annamycin posts 3× the CR rate of control in r/r AML — but runway expires before the confirmatory readout arrives

Updated 32d ago

Moleculin Biotech is a clinical-stage company developing an experimental cancer drug for relapsed or refractory acute myeloid leukemia that is not yet approved.

Annamycin, an anthracycline analog designed to avoid cardiotoxicity, showed 43% and 36% complete remission in two dose arms versus 12% control in relapsed/refractory AML at the 45-patient interim. The thesis resolves on whether comprehensive 90-patient Part A data, expected December 2026 to February 2027, confirms those rates and supports accelerated approval filing. Cash of roughly $17M funds operations only into Q1 2027, meaning a financing gap or dilutive raise before that readout is the most acute near-term threat.

Status

Challenged

Conviction

Current Thesis Drivers

45-patient interim: CR 43%/36% vs. 12% control, iDMC continued
No cardiotoxicity at cumulative doses exceeding anthracycline limits
Approvability via single-arm or randomized Part A data unresolved
Cash runway expires Q1 2027, coinciding with readout window

What could change the thesis?

Part A 90-patient readout: strong CR confirms path, weak data stalls NDA
Financing raise: non-dilutive deal extends runway, equity offering further dilutes
Part B enrollment 2028: completion on schedule validates program, delays pressure cash

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

2 programs · 8 catalysts

Stress Test